Based on the Appili Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Appili Therapeutics Inc is not available over the next 12 months. Appili Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Appili Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Appili Therapeutics Inc’s stock price was USD 0.03. Appili Therapeutics Inc’s stock price has changed by +0.00% over the past week, +3.59% over the past month and -3.70% over the last year.
No recent analyst target price found for Appili Therapeutics Inc
No recent average analyst rating found for Appili Therapeutics Inc
Company Overview Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Read Less
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibioti...Read More
Frequently Asked Questions About Appili Therapeutics Inc (APLIF) Stock
Stock Target Advisor's fundamental analysis for Appili Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on APLIF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on APLIF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on APLIF's stock to indicate if its overvalued.
The last closing price of APLIF's stock was USD 0.03.
The most recent market capitalization for APLIF is USD 3.15M.
Unfortunately we do not have enough analyst data on APLIF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Appili Therapeutics Inc's stock.
As per our most recent records Appili Therapeutics Inc has 0 Employees.
Appili Therapeutics Inc's registered address is #21-1344 Summer Street, Halifax, NS, Canada, B3H 0A8.
You can get more information about it from Appili Therapeutics Inc's website at https://appilitherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Appili Therapeutics Inc (APLIF) Stock
Stock Target Advisor's fundamental analysis for Appili Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on APLIF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on APLIF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on APLIF's stock to indicate if its overvalued.
The last closing price of APLIF's stock was USD 0.03.
The most recent market capitalization for APLIF is USD 3.15M.
Unfortunately we do not have enough analyst data on APLIF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Appili Therapeutics Inc's stock.
As per our most recent records Appili Therapeutics Inc has 0 Employees.
Appili Therapeutics Inc's registered address is #21-1344 Summer Street, Halifax, NS, Canada, B3H 0A8.
You can get more information about it from Appili Therapeutics Inc's website at https://appilitherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APLIF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
